2019-05-09T17:31:59-05:00 2018-06-30 941254756 HOOD & STRONG LLP 275 BATTERY ST STE 900 SAN FRANCISCO CA 94111 990 2017-07-01 030485196 MYELIN REPAIR FOUNDATION MYEL 4087610201 20111 EDINBURGH DRIVE SARATOGA CA 95070 SCOTT JOHNSON PRESIDENT 4087610201 2019-05-01 1 MAGA E KISRIEV P01008919 4157810793 12.201.129.210 2019-05-01 14:38:37 PD P D6D028B83EC7BAE48696A0FE418AC7215527A94E BB12664BE1E3D4BC08488640412F20C0F7A39D48 2017 2019-02-21 02:37:17Z SCOTT JOHNSON 20111 EDINBURGH DRIVE SARATOGA CA 95070 1077554 0 X WWW.MYELINREPAIR.ORG X 2002 CA ACCELERATING THE DEVELOPMENT OF NEW THERAPEUTICS TO PREVENT OR REPAIR DAMAGE TO MYELIN CAUSED BY MS. 5 4 2 4 0 0 50000 1007500 15000 0 0 0 0 70054 65000 1077554 0 306439 0 0 142086 166715 0 0 30215 41049 116030 183135 589184 -118135 488370 840688 1627215 1160 299317 839528 1327898 X TO ACCELERATE THE DEVELOPMENT OF NEW THERAPEUTICS TO PREVENT OR REPAIR DAMAGE TO MYELIN CAUSED BY MULTIPLE SCLEROSIS. THE MRF IS HELPING TO IDENTIFY BIOMARKERS OF MYELIN REPAIR FOR USE IN MYELIN REPAIR DRUG DEVELOPMENT AND CLINICAL TRIALS. 0 0 514525 306439 70054 IMAGING GRANTS FOR EXPERIMENTS TO IDENTIFY POTENTIAL BIOMAKERS OF MYELIN REPAIR TO MULTIPLE SCLEROSIS - MRF HAS DEVELOPED AND FUNDED 5 EXPERIMENTS.DETAILS OF THE EXPERIMENT CONDUCTED INCLUDE, BUT ARE NOT LIMITED TO: - DETERMINE IF T1R CAN DISTINGUISH INJURED MYELIN FROM HEALTHY MYELIN IN THE BRAIN;- LOOK FOR DIFFERENT PATTERN OF METABOLITES IN DEMYELINATING BRAIN VS. REMYELINATING;- DETERMINE IF RETINAL IMAGING CAN MEASURE INJURY AND REPAIR IN CENTRAL NERVOUS SYSTEM;-DETERMINE IF A CLINICAL TRIAL FRIENDLY VERSION OF MTR CAN ASSESS REPAIR OF MS LESIONS;-DETERMINE IF MWI CAN BE A GOOD MARKER OF ROBUST MYELIN REPAIRMRF HAS ALSO COLLABORATED WITH BIOGEN INC., THE LEADER IN IMMUNE SUPPRESSIVE THERAPIES FOR MS.THE GOALS OF THE EXPERIMENTS CONDUCTED ARE: 1. DETERMINE IF ANY OF THESE PILOT EXPERIMENTS INDICATE IF THEY COULD LEAD TO A BIOMARKER OF MYELIN REPAIR; 2. WORK WITH EXPERTS TO IDENTIFY ADDITIONAL POSSIBLE IMAGING STRATEGIES THAT COULD BE EVALUATED EXPERIMENTALLY FOR THEIR POTENTIAL TO BE USED AS A BIOMARKER.BIOFLUID GRANTS FOR EXPERIMENTS TO IDENTIFY POTENTIAL BIOMARKERS OF MYELIN REPAIR IN MULTIPLE SCLEROSIS - MRF HAS DEVELOPED AND FUNDED 2 EXPERIMENTS.DETAILS OF THE EXPERIMENT CONDUCTED INCLUDE, BUT ARE NOT LIMITED TO:- LOOK FOR DIFFERENCES IN CEREBRAL SPINAL FLUID (CSF) FROM MS PATIENTS BETWEEN GOOD AND BAD REPAIRERS;- LOOK FOR MOLECULAR BASIS IN CSF AND BLOOD FROM MS PATIENTS FOR THE INHIBITION OF REMYELINATION WHICH COULD BE A BIOMARKER.THE GOALS OF THE EXPERIMENTS CONDUCTED ARE: 1. DETERMINE IF ANY OF THESE PILOT EXPERIMENTS INDICATE IF THEY COULD LEAD TO A BIOMARKER OF MYELIN REPAIR; 2. WORK WITH EXPERTS TO IDENTIFY ADDITIONAL POSSIBLE IMAGING STRATEGIES THAT COULD BE EVALUATED EXPERIMENTALLY FOR THEIR POTENTIAL TO BE USED AS A BIOMARKER.INTERNATIONAL PORTFOLIO OF EXPERIMENTS -MRF HAS PROVIDED GRANTS TO THE FOLLOWING DOMESTIC AND FOREIGN ORGANIZATIONS:DOMESTIC GRANTS: STANFORD UNIVERSITY AND OREGON HEALTH & SCIENCE UNIVERSITYFOREIGN GRANTS: CANADA - MCGILL UNIVERSITY, SWEDEN- KAROLINASKA INSTITUTE, SWITZERLAND- UNIVERSITY OF ZURICHTO REVIEW THE MOST RECENT SCIENTIFIC WORK AND MEET WITH LEADING SCIENTISTS, AND ATTENDED THE FOUR MAJOR WORLDWIDE CONFERENCES THAT ADDRESS MS AND MYELIN REPAIR- ECTRIMS ( EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MS) IN PARIS, FRANCE-ACTRIMS ( AMERICAN COMMITTEE FOR TREATMENT AND RESEARCH IN MS ) IN SAN DIEGO, CA-AAN ( AMERICAN ACADEMY OF NEUROLOGY) IN LOS ANGELES CA-EAN ( EUROPEAN ACADEMY OF NEUROLOGY) IN LISBON, PORTUGALTHE GOALS OF PROVIDING GRANTS ARE- 1. BUILD AWARENESS AMONG THE SCIENTIFIC COMMUNITY OF OUR MISSION; 2. STIMULATE NEW IDEAS TO EXPLORE TO UNCOVER MYELIN REPAIR BIOMARKERS; 3. EXPLORE POSSIBLE SCIENTIFIC AVENUES IN ADDITION TO IMAGING AND BIOFLUIDS. 514525 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 0 1 2 1 0 0 0 0 0 1 1 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA X X LOUISE SAVOIE 4087610201 3575 MONROE ST 309 SANTA CLARA CA 95051 CASEY MCGLYNN DIRECTOR 1.00 X 0 0 0 BOBBY MEHTA DIRECTOR 1.00 X 0 0 0 ANDY CATES DIRECTOR 1.00 X 0 0 0 JIM GIDWITZ DIRECTOR 1.00 X 0 0 0 SCOTT JOHNSON CEO 30.00 X X 147315 0 0 147315 0 0 1 0 0 0 0 1007500 1007500 OTHER INCOME - RETURN 900099 70054 70054 70054 1077554 70054 0 0 X 106000 106000 200439 200439 141057 91687 23980 25390 1104 1104 14492 9420 2464 2608 10062 6540 1711 1811 7790 7790 90764 90764 9263 1462 7395 406 8213 8213 589184 514525 44444 30215 840688 994215 0 633000 840688 1627215 1160 299317 1160 299317 X 839528 1327898 839528 1327898 840688 1627215 488370 0 X 0 0 0 X 3463318 2660019 216766 50000 1007500 7397603 3463318 2660019 216766 50000 1007500 7397603 3308495 4089108 1256 392 1648 21665 106579 70054 198298 7597549 365000 0.53820 0.55320 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2013 AMOUNT: $ 21,665. 2014 AMOUNT: $ 40. 2017 AMOUNT: $ 70,054. REIMBURSED LEGAL FEES - 2014 AMOUNT: $ 106,539. 1 NORTH AMERICA 0 0 GRANTMAKING 103000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 97439 0 0 0 0 0 0 200439 0 200439 NORTH AMERICA SCIENTIFIC RESEARCH 103000 CASH PROGRESS PAYMENTS CONTRACTUAL AMOUNT EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 34239 CASH PROGRESS PAYMENTS CONTRACTUAL AMOUNT EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH 63200 CASH PROGRESS PAYMENTS CONTRACTUAL AMOUNT 3 0 0 0 0 0 0 0 PART I, LINE 2: GRANTS OUTSIDE THE U.S. ARE TREATED THE SAME AS GRANTS WITHIN THE U.S. WITH REGULAR REQUIRED REPORTS AND CONVERSATIONS WITH THE RECIPIENTS. 1 STANFORD UNIVERSITY 3160 PORTER DR STANFORD CA 94304 941156365 501(C)(3) 60000 SCIENTIFIC EXPERIMENT OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97239 46000 SCIENTIFIC EXPERIMENT 1 1 PART I, LINE 2: THE UNIVERSITY IS SUBJECT TO TERMS AND CONDITIONS OF THE SPONSORED RESEARCH AGREEMENT BETWEEN THE UNIVERSITY AND THE MRF. THE RESEARCHER'S WORK IS REVIEWED BY THE MRF EXECUTIVE COMMITTEE AND BY THE MRF PRESIDENT. FORM 990, PART VI, SECTION B, LINE 11B THE TAXPAYER'S ACCOUNTING FIRM FORWARDS THE FORM 990 TO THE CEO FOR REVIEW. ONCE THE CEO APPROVES THE FORM 990 IT IS THEN FORWARDED TO THE BOARD MEMBERS FOR THEIR REVIEW PRIOR TO FILING. BOARD MEMBERS ARE ENCOURAGED TO REVIEW THE FORM AND TO FORWARD THEIR QUESTIONS, IF ANY, TO THE CEO. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS, DRECTORS AND KEY EMPLOYEES ARE COVERED. ANY AND ALL CONFLICTS ARE REVIEWED BY DISINTERESTED BOARD MEMBERS AND, IF NEEDED, BY LEGAL COUNSEL. PERSONS WITH A CONFLICT OF INTEREST WILL BE RESTRICTED FROM MAKING KEY DECISIONS FOR MRF AS THEY RELATE TO THE INTEREST UNLESS OTHERWISE APPROVED BY THE MAJORITY OF THE DISINTERESTED BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15A CEO COMPENSATION IS DETERMINED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS, GOVERNING DOCUMENTS AND POLICIES ARE AVAILABLE UPON REQUEST FOR THE SAME PERIOD OF TIME SET FORTH IN SEC. 6104(D). FORM 990, PART IX, LINE 11G CONSULTING SERVICES: PROGRAM SERVICE EXPENSES 90,764. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 90,764.